Exploiting metabolic vulnerabilities in breast cancers with NF1 loss

Cell Rep Med. 2023 Apr 18;4(4):101010. doi: 10.1016/j.xcrm.2023.101010.

Abstract

Auf der Maur et al.1 identify neurofibromin 1 (NF1) loss as a mechanism of resistance to PI3K inhibitor in breast cancer cells. NF1 loss leads to enhanced glycolysis, which may be targeted with the antioxidant N-acetyl cysteine (NAC).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biochemical Phenomena*
  • Breast Neoplasms* / drug therapy
  • Female
  • Humans
  • Neurofibromin 1 / genetics
  • Neurofibromin 1 / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism

Substances

  • Neurofibromin 1
  • Phosphatidylinositol 3-Kinases